Literature DB >> 15186520

The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002.

Sodsai Tovanabutra1, Chris Beyrer, Supachai Sakkhachornphop, Myat Htoo Razak, Gabriela L Ramos, Tassanai Vongchak, Kittipong Rungruengthanakit, Pongpran Saokhieo, Kwanchanok Tejafong, Bohye Kim, Mark De Souza, Merlin L Robb, Deborah L Birx, Jaroon Jittiwutikarn, Vinai Suriyanon, David D Celentano, Francine E McCutchan.   

Abstract

CRF01_AE and subtype B have dominated the HIV-1 epidemic in Thailand since 1989. We reported a new circulating recombinant form of HIV-1, CRF15_01B, as well as other unique CRF01_AE/B recombinants among prevalent HIV infections in Thailand. We sought to study this challenging molecular picture through assessment of subtypes among recent HIV-1 seroconverters in northern Thai drug users. A total of 847 HIV-1 seronegative drug users (342 IDU and 505 non-IDU) were enrolled, from 1999 to 2002, in a prospective study; 39 HIV-1 incident cases were identified and characteristics were collected. The overall HIV-1 incidence rate was 2.54/100PY, but it was 10.0/100PY among male IDU. HIV was strongly associated with injection history; 38 of 39 seroconverters gave a history of IDU. A near full-length genome of HIV-1 was recovered by PCR amplification and sequenced from peripheral mononuclear cell extracted DNA of 38 seroconverters. Phylogenetic analysis revealed that 33 (86.8%) were CRF01_AE and 5 (13.2%) were CRF01_AE/B recombinants. These recombinants had different structure but shared some common breakpoints, indicating an ongoing recombination process. Recombinant infection increased with year of sampling (0 to 57.1%). The molecular epidemiology of HIV-1 among drug users in northern Thailand has thus entered a new era. CRF01_AE remains predominant while pure subtype B is becoming rare, and now a substantial component of the epidemic. These findings support the need for CRF01_AE and subtype B components in clade-matched vaccine strategies for Thai phase III trials. Ongoing molecular surveillance of circulating HIV-1 strains is imperative for the evaluation of HIV vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186520     DOI: 10.1089/088922204323087705

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  22 in total

1.  Near full-length genomic characterization of a HIV type 1 BC recombinant strain from Manipur, India.

Authors:  Roni Sarkar; Kamalesh Sarkar; N Brajachand Singh; Y Manihar Singh; Sekhar Chakrabarti
Journal:  Virus Genes       Date:  2012-06-19       Impact factor: 2.332

2.  Distinct circulating recombinant HIV-1 strains among injecting drug users and sex workers in Afghanistan.

Authors:  Eric Sanders-Buell; Meera Bose; Abdul Nasir; Catherine S Todd; M Raza Stanekzai; Sodsai Tovanabutra; Paul T Scott; Steffanie A Strathdee; Jeffrey Tjaden; Nelson L Michael; Francine E McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

3.  The indonesian variants of CRF33_01B: Near-full length sequence analysis.

Authors:  Ivo N SahBandar; Kiyomi Takahashi; Kazushi Motomura; Zubairi Djoerban; Iman Firmansyah; Katsuhiko Kitamura; Hironori Sato; Herdiman T Pohan; Shigehiro Sato
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-19       Impact factor: 2.205

4.  HIV diversity, molecular epidemiology, and the role of recombination.

Authors:  Gustavo H Kijak; Francine E McCutchan
Journal:  Curr Infect Dis Rep       Date:  2005-11       Impact factor: 3.725

5.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

Review 6.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

7.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

8.  Comprehensive Characterization of HIV-1 Molecular Epidemiology and Demographic History in the Brazilian Region Most Heavily Affected by AIDS.

Authors:  Tiago Gräf; Hegger Machado Fritsch; Rúbia Marília de Medeiros; Dennis Maletich Junqueira; Sabrina Esteves de Matos Almeida; Aguinaldo Roberto Pinto
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 9.  Time to act: a call for comprehensive responses to HIV in people who use drugs.

Authors:  Chris Beyrer; Kasia Malinowska-Sempruch; Adeeba Kamarulzaman; Michel Kazatchkine; Michel Sidibe; Steffanie A Strathdee
Journal:  Lancet       Date:  2010-08-14       Impact factor: 79.321

10.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.